NT-proBNP: A cardiac biomarker to assess prognosis in non-Hodgkin lymphoma

Eva Gimeno, Miquel Gómez, Juan Ramón González, Josep Comín, Alberto Alvarez-Larrán, Blanca Sánchez-González, Lluis Molina, Eva Domingo-Domenech, Francesc Garcia-Pallarols, Carmen Pedro, Eugenia Abella, Carles Vilaplana, Silvia de Sanjosé, Carlos Besses, Antonio Salar

    Research output: Contribution to journalArticleResearchpeer-review

    19 Citations (Scopus)


    NT-proBNP provides diagnostic and prognostic information in heart syndromes but its role in cancer has not yet been established. The prognostic value of NT-proBNP was prospectively studied in 104 non-Hodgkin lymphoma (NHL) patients treated with chemotherapy. Echocardiography and NT-proBNP were determined prior to treatment. In multivariate analysis, NT-proBNP ≥ 900. pg/ml was the variable with higher risk of death (adjusted hazard ratio 11.1; 95% CI 3.8-32.9; P< 0.001). The C statistic for NT-proBNP ≥ 900 pg/ml was significantly better than IPI score for prediction of survival. These findings suggest that NT-proBNP ≥ 900. pg/ml could be considered a useful marker for risk assessment in NHL patients treated with chemotherapy. © 2011 Elsevier Ltd.
    Original languageEnglish
    Pages (from-to)715-720
    JournalLeukemia Research
    Issue number6
    Publication statusPublished - 1 Jun 2011


    • Non-Hodgkin lymphoma
    • NT-proBNP
    • Prognostic factor

    Fingerprint Dive into the research topics of 'NT-proBNP: A cardiac biomarker to assess prognosis in non-Hodgkin lymphoma'. Together they form a unique fingerprint.

    Cite this